Pfizer reported better-than-expected Q1 2024 results, demonstrating resilience to the decline in COVID-19 vaccine and drug sales. The company raised its full-year earnings guidance on the back of cost cuts, strong sales of its Prevnar pneumococcal vaccine, and a smaller-than-expected decline in sales of its Paxlovid COVID-19 treatment. The better-than-expected results sent the stock up about 1.5% in premarket trading.
Revenue:
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app- Total revenue was $14.90 billion, down 19% year-over-year but above analysts' expectations of $13.92 billion.
- The decline was largely due to lower sales of the Comirnaty COVID-19 vaccine and Paxlovid.
- Excluding these two drugs, revenue grew 11% year-over-year.
- Comirnaty sales were $354 million in the first quarter, below analysts' expectations of $496.5 million. However, Pfizer expects the vast majority of Comirnaty sales to come in the second half of the year, primarily in the fourth quarter.
- Sales of the company's leading pneumococcal vaccine franchise (Prevnar) were $1.69 billion, exceeding expectations of $1.66 billion.
- Paxlovid sales were $2.04 billion, above expectations of $762.5 million.
Earnings:
- Non-GAAP EPS was $0.82, well above analysts' expectations of $0.51.
- The company raised its full-year adjusted EPS guidance to $2.15-$2.35 (previously $2.21).
Other Key Points from the Earnings Report:
- Pfizer maintained its full-year sales guidance for Comirnaty and Paxlovid of $8 billion.
- The company is continuing to execute its $4 billion cost-savings program and internal restructuring.
- Pfizer recently acquired oncology drugmaker Seagen for $43 billion.
- The company recorded a favorable adjustment of $771 million in the quarter due to renegotiating its contract with the U.S. government to return unused Paxlovid inventory.
The company's shares are up in premarket trading. It is worth noting that the company is showing increasing resilience to the decline in COVID-related sales as the pandemic wanes. Additionally, the company's dividend yield is 6.5%, making its shares attractive as they have fallen to their lowest levels since 2013.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
